Natixis Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD

Natixis Advisors LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 646,396 shares of the biopharmaceutical company’s stock after purchasing an additional 17,725 shares during the period. Natixis Advisors LLC owned about 0.05% of Gilead Sciences worth $71,750,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its position in Gilead Sciences by 132.1% in the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 25,300 shares of the biopharmaceutical company’s stock valued at $2,808,000 after purchasing an additional 14,400 shares during the last quarter. Korea Investment CORP raised its holdings in shares of Gilead Sciences by 18.3% in the third quarter. Korea Investment CORP now owns 1,351,318 shares of the biopharmaceutical company’s stock valued at $149,996,000 after buying an additional 209,246 shares during the last quarter. Grantham Mayo Van Otterloo & Co. LLC boosted its stake in shares of Gilead Sciences by 283.7% during the third quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 91,973 shares of the biopharmaceutical company’s stock worth $10,209,000 after buying an additional 68,006 shares during the period. Munich Reinsurance Co Stock Corp in Munich purchased a new stake in Gilead Sciences during the 3rd quarter valued at approximately $67,500,000. Finally, Ameriflex Group Inc. lifted its position in Gilead Sciences by 92.5% during the 3rd quarter. Ameriflex Group Inc. now owns 2,480 shares of the biopharmaceutical company’s stock worth $275,000 after acquiring an additional 1,192 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Down 0.7%

Shares of GILD stock opened at $144.08 on Monday. The business’s fifty day moving average price is $138.29 and its 200 day moving average price is $125.85. The firm has a market capitalization of $178.86 billion, a PE ratio of 21.28, a P/E/G ratio of 1.89 and a beta of 0.36. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GILD shares. Daiwa Securities Group upped their price target on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Monday, February 23rd. Finally, Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Twenty-three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $156.72.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 309,280 shares of company stock worth $43,935,470 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.